Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma


A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas


Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.


Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.

Study Status: Completed


Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: atrasentan hydrochloride Phase 1

Verified by National Cancer Institute (NCI) August, 2004

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI) identifier: NCT00017264

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Surasak Phuphanich, MD, FAAN., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site